1. Scrip
  2. >>Rare Diseases

Sangamo Can Take Lead In Fabry Gene Therapy

Gearing Up For Phase III

 
• By Andrew McConaghie

Avrobio dropping out of the race means Sangamo can take advantage but its gene therapy must show long-term efficacy in patients not receiving enzyme replacement therapy.

Sangamo
The Fabry disease gene therapy is one of three candidates Sangamo has in its wholly-owned pipeline • Source: Alamy

After its biggest competitor AVROBIO fell behind in the battle to develop the first ever Fabry disease gene therapy, Sangamo Therapeutics could now be in a position to win the race to market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.